Researchers have identified two new panRAF inhibitors that they believe may could be used to treat patients with BRAF- or NRAS-mutant melanomas, or those patients who have developed resistance to BRAF inhibitors.
MRV Research
New technology directly reprograms skin fibroblasts for a new role
As the main component of connective tissue in the body, fibroblasts are the most common type of cell. Taking advantage of that ready availability, scientists from the Perelman School of Medicine at the University of Pennsylvania, the Wistar Institute, Boston University School of Medicine, and New Jersey Institute of Technology have discovered a way to repurpose fibroblasts into functional melanocytes, the body’s pigment-producing cells. The technique has immediate and important implications for developing new cell-based treatments for skin diseases such as vitiligo, as well as new screening strategies for melanoma. The work was published this week in Nature Communications.
NOVOGEN ANNOUNCES BREAKTHROUGH DISCOVERY IN THE TREATMENT OF MELANOMA
16 December 2014, Sydney, Australia: Australian/US biotechnology company, Novogen Limited, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma.
Genentech Submits NDA For Cobimetinib With Zelboraf To Treat Advanced Melanoma
Genentech, a part of Swiss pharmaceutical giant Roche Holding AG (RHHBY.PK, ROG.SW, RO.SW), Monday announced that it has submitted a New Drug Application or NDA to the U.S. Food and Drug Administration or FDA for Investigational Cobimetinib used in combination with Zelboraf (vemurafenib).